A
Andres Poveda Velasco
Researcher at University of Adelaide
Publications - 5
Citations - 270
Andres Poveda Velasco is an academic researcher from University of Adelaide. The author has contributed to research in topics: Imatinib mesylate & Interim analysis. The author has an hindex of 4, co-authored 4 publications receiving 199 citations.
Papers
More filters
Journal ArticleDOI
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
Paolo G. Casali,Axel Le Cesne,Andres Poveda Velasco,Dusan Kotasek,Piotr Rutkowski,Peter Hohenberger,Elena Fumagalli,Ian Judson,Antoine Italiano,Hans Gelderblom,Antoine Adenis,Jörg T. Hartmann,Florence Duffaud,David Goldstein,Javier Martin Broto,Alessandro Gronchi,Angelo Paolo Dei Tos,Sandrine Marreaud,Winette T. A. van der Graaf,Winette T. A. van der Graaf,John Zalcberg,Saskia Litière,Jean-Yves Blay +22 more
TL;DR: In this article, an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST) was conducted.
Journal ArticleDOI
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
Alessandro Gronchi,Sylvie Bonvalot,Andres Poveda Velasco,Dusan Kotasek,Piotr Rutkowski,Peter Hohenberger,Elena Fumagalli,Ian Judson,Antoine Italiano,Hans Gelderblom,Frits van Coevorden,Nicolas Penel,Hans-Georg Kopp,Florence Duffaud,David Goldstein,Javier Martin Broto,Eva Wardelmann,Sandrine Marreaud,Mark Smithers,Axel Le Cesne,Facundo Zaffaroni,Saskia Litière,Jean-Yves Blay,Paolo G. Casali +23 more
TL;DR: A post hoc observational study on patients included in the randomized, open-label, phase III trial on adjuvant imatinib to assess the risk of death with and withoutImatinib according to microscopic margins status (R0/R1), finding the difference in OS by quality of surgery with or without imatinIB was associated with the presence of tumor rupture.
Journal ArticleDOI
Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial.
Paolo G. Casali,Axel Le Cesne,Andres Poveda Velasco,Dusan Kotasek,Piotr Rutkowski,Peter Hohenberger,Elena Fumagalli,Ian Judson,Antoine Italiano,Javier Martin Broto,Alessandro Gronchi,Angelo Paolo Dei Tos,Sandrine Marreaud,Winette T. A. van der Graaf,John Zalcberg,Saskia Litière,Jean-Yves Blay +16 more
TL;DR: A planned interim analysis carried out after 115 events according to the new primary end-point into IFS is reported, with a si...
Journal ArticleDOI
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS) ☆
Paolo G. Casali,Paolo G. Casali,A. Le Cesne,Andres Poveda Velasco,Dusan Kotasek,P. Rutkowski,P. Hohenberger,Elena Fumagalli,Elena Fumagalli,Ian Judson,Antoine Italiano,Hans Gelderblom,Nicolas Penel,Joerg T. Hartmann,Florence Duffaud,David Goldstein,Javier Martin-Broto,Alessandro Gronchi,E. Wardelmann,Sandrine Marreaud,John Zalcberg,Saskia Litière,J.-Y. Blay +22 more
TL;DR: The Swedish/German trial as mentioned in this paper showed a small but significant long-term OS benefit in high-risk GIST patients treated with 3 years of adjuvant imatinib compared with no further therapy after R0-R1 surgery.
Journal ArticleDOI
531P Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial
Andres Poveda Velasco,Stephanie Lheureux,N. Colombo,David Cibula,Mari Bunkholt Elstrand,J. I. Weberpals,Maria Bjurberg,Ana Oaknin,Monika Sikorska,Antonio Gonzalez Martin,R Madry,M. Rubio Perez,Jonathan A. Ledermann,O. Ozgoren,Alan Barnicle,Helen Marshall,Zeenat Bashir,Erik Škof +17 more
TL;DR: The Phase IIIb, single-arm OPINION study reported a median progression-free survival (PFS) of 9.2 months (mo) with maintenance olaparib in pts with non-gBRCAm PSR OC as mentioned in this paper .